Patents by Inventor Patricia Spilman

Patricia Spilman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
    Patent number: 11370793
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: June 28, 2022
    Assignee: NantNeuro, LLC
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Triazolopyridines And Triazolopyrimidines That Lower Stress-Induced P-Tau
    Publication number: 20220024935
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 27, 2022
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Compositions for APP-selective BACE inhibition and uses therefor
    Patent number: 11142505
    Abstract: Selected compounds, compositions, and methods for inhibiting BACE are presented that have relatively high selectivity towards APP via interaction of the inhibitor with both BACE and APP.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: October 12, 2021
    Assignee: The Regents of the University of California
    Inventors: Varghese John, Patricia Spilman, Barbara Jagodzinska
  • GP130 modulators
    Patent number: 10947207
    Abstract: There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: March 16, 2021
    Assignee: The Regents of the University of California
    Inventors: Mohammad Parvez Alam, Varghese John, Patricia Spilman, Kanagasabai Vadivel
  • GP130 MODULATORS
    Publication number: 20190292161
    Abstract: There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
    Type: Application
    Filed: August 4, 2017
    Publication date: September 26, 2019
    Inventors: Mohammad Parvez Alam, Varghese John, Patricia Spilman, Kanagasabai Vadivel
  • Compositions For APP-Selective BACE Inhibition And Uses Therefor
    Publication number: 20190077766
    Abstract: Selected compounds, compositions, and methods for inhibiting BACE are presented that have relatively high selectivity towards APP via interaction of the inhibitor with both BACE and APP.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 14, 2019
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Triazolopyridines And Triazolopyrimidines That Lower Stress-Induced P-Tau
    Publication number: 20190048012
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Application
    Filed: August 29, 2016
    Publication date: February 14, 2019
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska